Opinion statement While no PD-1 inhibitor has been FDA approved for use in sarcoma or
proven efficacious in a randomized trial, the use of single agent PD-1 inhibitors is standard …

Importance Anthracycline-based therapy is standard first-line treatment for most patients with
advanced and metastatic sarcomas. Although multiple trials have attempted to show …

Importance Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options,
and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) …

Ewing sarcoma (ES) is an aggressive malignant tumor, characterized by non-random
chromosomal translocations that produce fusion genes. Fusion genes and fusion protein …

Background Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue
sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the …

One obstacle for human solid tumor immunotherapy research is the lack of clinically relevant
animal models. In this study, we sought to establish a chimeric antigen receptor (CAR) T-cell …

Ewing's sarcoma (ES) is an aggressive malignant tumor commonly affecting adolescents.
The standard of care includes surgical treatment and systemic therapies, although ES …

BACKGROUND External ventricular drains (EVDs) measure intracranial pressure, divert
cerebrospinal fluid, and allow for orthotropic administration of pharmacologic agents …

Background Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are ideal
solid tumors for the development of adoptive cellular therapy (ACT) targeting NY-ESO-1, as …

Simple Summary Ewing sarcoma (ES) is one of the most common kinds of cancer in
youngsters, and ES relapse after therapy treatment remains a problem. Carbonic …